Nexstim Plc SmartFocusTM TMS technology based therapy used across all university hospitals in Finland

Press Release, Helsinki, 18 June 2018, at 11:00 AM

Nexstim Plc SmartFocusTM TMS technology based therapy used across all university hospitals in Finland   

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”), the targeted neuromodulation company developing and commercializing its world-leading navigated non-invasive brain stimulation technology for therapeutic and diagnostic applications, provides an update on use of its SmartFocusTM TMS (transcranial magnetic stimulation) technology for therapeutic applications across Finnish university hospitals.

All university hospitals in Finland use Nexstim’s technology to treat depression, pain or both indications and are currently administering ~200-1000 therapy sessions/year/system:

  • University of Helsinki –  pain 
  • University of Turku – depression and pain
  • University of Eastern Finland (Kuopio) – depression and pain
  • University of Tampere – depression
  • University of Oulu – depression

TMS has demonstrated efficacy in the treatment of depression and chronic neuropathic pain. Use of Nexstim’s technology in these therapeutic indications is the only personalised, navigated TMS approach, providing physicians with confidence in accurate targeting of the TMS to the specific area of the brain associated with the indication, through its unique 3D navigation system, based on a patient’s individual MRI scan.

“Visualization of the therapy in the brain inspires confidence in both the patient and the physician. In Oulu University Hospital we use Nexstim’s navigated TMS technology for depression treatment. Treatment using this system has very few adverse effects compared to other treatments in this indication”, comments Marja-Liisa Kemppainen MD, Psychiatry Department, Oulu University Hospital.

“Nexstim’s technology is in my experience well-validated, continuously evolving and the most user-friendly navigated TMS system available. That is why we use the technology for clinical therapy in both depression and pain, presurgical mapping and for clinical research”, states Petro Julkunen, Professor, Assistant Chief Physicist, Kuopio University Hospital.

“Department of Clinical Neurophysiology in Tampere Medical Imaging Centrum uses Nexstim’s technology mostly for depression treatment but to an ever-increasing degree for pain treatments too and for presurgical mapping.  Nexstim’s technology is easy to carry out and has few adverse effects,” comments Mirja Tenhunen, Assistant Chief Physicist, Tampere University Hospital.

Martin Jamieson, Chairman and CEO, Nexstim Plc commented: “We are pleased to have established frequent usage and confidence across local physicians in the use of our technology for the treatment of depression and pain, with continued positive feedback on the unique navigation and visualisation capabilities of our systems. We look forward to continuing this great progress in Finland.”

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                                                                                                                                                                      
Martin Jamieson, Chairman and CEO   +44 77 1516 3942
martin.jamieson@nexstim.com

Citigate Dewe Rogerson    +44 (0)207 2822949
David Dible/Shabnam Bashir/Isabelle Andrews   david.dible@citigatedewerogerson.com

About Nexstim Plc
Nexstim is a targeted neuromodulation company focused on developing and commercializing its world-leading navigated non-invasive brain stimulation technology, known as SmartFocusTM TMS (transcranial magnetic stimulation), for therapeutic applications, namely stroke, depression and chronic pain via its Navigated Brain Therapy (NBT®) system.

Nexstim has launched its NBT® system in the US for the treatment of Major Depressive Disorder (MDD) following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.

The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the US.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

Attachment

Leave a Comment